KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GoodRx Holdings (GDRX) Accumulated Expenses (2019 - 2025)

GoodRx Holdings' Accumulated Expenses history spans 7 years, with the latest figure at $86.7 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 4.05% year-over-year to $86.7 million; the TTM value through Dec 2025 reached $86.7 million, up 4.05%, while the annual FY2025 figure was $86.7 million, 4.05% up from the prior year.
  • Accumulated Expenses for Q4 2025 was $86.7 million at GoodRx Holdings, down from $143.4 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $143.4 million in Q3 2025 and bottomed at $8.5 million in Q1 2022.
  • The 5-year median for Accumulated Expenses is $68.4 million (2023), against an average of $60.8 million.
  • The largest YoY upside for Accumulated Expenses was 467.26% in 2022 against a maximum downside of 75.74% in 2022.
  • A 5-year view of Accumulated Expenses shows it stood at $15.5 million in 2021, then soared by 206.74% to $47.5 million in 2022, then soared by 50.09% to $71.3 million in 2023, then grew by 16.83% to $83.3 million in 2024, then rose by 4.05% to $86.7 million in 2025.
  • Per Business Quant, the three most recent readings for GDRX's Accumulated Expenses are $86.7 million (Q4 2025), $143.4 million (Q3 2025), and $95.7 million (Q2 2025).